AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23027490 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation
Number of subjects: 108
Study 16053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 1 mg
Number of subjects: 64
Study 16053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg
Number of subjects: 64
Study 16053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Number of subjects: 64
Study 16053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg
Number of subjects: 64
Study 16053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (all doses combined)
Number of subjects: 64
Study 12449286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Intervention Program (IIP) with motivational interviewing contacts from a dietitian
Number of subjects: 175
Study 12449286 — intervention group
Group type: COMPARATOR
Intervention: Usual WHI Dietary Modification (DM) Intervention
Number of subjects: 175
Study 12449286 — intervention group
Group type: COMPARATOR
Intervention: Overall difference between IIP intervention and control
Number of subjects: 175
Study 9880769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-fluorouracil-based)
Number of subjects: 0
Study 9880769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (various drugs including gemcitabine)
Number of subjects: 0
Study 9880769 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (not specified)
Number of subjects: 0
Study 9880769 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 7701406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 43
Study 7701406 — intervention group
Group type: COMPARATOR
Intervention: Standard Heparin (UFH)
Number of subjects: 43
Study 2730380 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0
Study 2730380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 791101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 0
Study 791101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephapirin
Number of subjects: 0
Study 791101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0
Study 791101 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study 30593164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 100
Study 30593164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27855723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral pathway
Number of subjects: 197
Study 27855723 — intervention group
Group type: EXPERIMENTAL
Intervention: In-consultation pathway
Number of subjects: 197
Study 27855723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral and in-consultation pathways
Number of subjects: 197
Study 27855723 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice deprivation
Number of subjects: 197
Study 27855723 — intervention group
Group type: COMPARATOR
Intervention: Practice list size
Number of subjects: 197
Study 27855723 — intervention group
Group type: COMPARATOR
Intervention: Practice deprivation decile
Number of subjects: 197
Study 25001950 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone reactivity on the first day (competition effect)
Number of subjects: 0
Study 25001950 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone reactivity on the second day
Number of subjects: 0
Study 25001950 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone fluctuations on the second day in unstable hierarchies
Number of subjects: 0
Study 22278973 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (8 weeks)
Number of subjects: 24
Study 21214105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (5 mg/kg)
Number of subjects: 120
Study 21214105 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 18661524 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90-labeled murine HMFG1 plus standard treatment (AT)
Number of subjects: 407
Study 18661524 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (ST)
Number of subjects: 407
Study 16038388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild to moderate hypothermia (32 degrees‐28 degrees C) during CABG surgery
Number of subjects: 45
Study 16038388 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HIPA
Number of subjects: 45
Study 16038388 — intervention group
Group type: COMPARATOR
Intervention: Patients without HIPA
Number of subjects: 45
Study 12439651 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking 30 min, 5 days per week (DEX1)
Number of subjects: 56
Study 12439651 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking 60 min, 5 days per week (DEX2)
Number of subjects: 56
Study 12439651 — intervention group
Group type: COMPARATOR
Intervention: Diet only control group (DO)
Number of subjects: 56
Study 10363736 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (15 mg/kg)
Number of subjects: 334
Study 10363736 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (7.5 mg/kg)
Number of subjects: 334
Study 7572831 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session preventive intervention program
Number of subjects: 271
Study 7572831 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment condition
Number of subjects: 271
Study 2115287 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position exercise
Number of subjects: 30
Study 2115287 — intervention group
Group type: COMPARATOR
Intervention: Supine position exercise
Number of subjects: 30
Study 7234386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled human milk feeding regimen, protein intake: 2.0 g/kg/day
Number of subjects: 20
Study 7234386 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk based infant formula feeding regimen, protein intake: 4.4 g/kg/day
Number of subjects: 20
Study 31939511 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Environment (VLE) - six virtual pediatric rheumatology modules
Number of subjects: 92
Study 31939511 — intervention group
Group type: COMPARATOR
Intervention: Control group - only answered the pre-course test and post-course test after 4 weeks
Number of subjects: 92
Study 31939511 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with VLE use
Number of subjects: 92
Study 31097609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led CKD management program in intervention practices
Number of subjects: 23657
Study 31097609 — intervention group
Group type: COMPARATOR
Intervention: Usual CKD care in control practices
Number of subjects: 23657
Study 28229374 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (36 hours)
Number of subjects: 12
Study 28229374 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 12
Study 26352793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-saving group (Technolas 217z Zyoptix laser; Bausch & Lomb)
Number of subjects: 80
Study 26352793 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized group (WaveLight Allegretto Wave Eye‐Q laser; Alcon Laboratories)
Number of subjects: 80
Study 26352793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-saving group
Number of subjects: 80
Study 26352793 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized group
Number of subjects: 80
Study 26352793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 22960802 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based case-management intervention
Number of subjects: 268
Study 22960802 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 21299844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6-12 mg/day
Number of subjects: 421
Study 21299844 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 2-4 mg/day
Number of subjects: 421
Study 21299844 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4-6 mg/day
Number of subjects: 421
Study 20024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 871
Study 20024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 871
Study 20024739 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) use
Number of subjects: 871
Study 17901665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified EBM
Number of subjects: 0
Study 17901665 — intervention group
Group type: COMPARATOR
Intervention: EBM only
Number of subjects: 0
Study 12709690 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin
Number of subjects: 29
Study 12709690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 29
Study 10736079 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (n=14)
Number of subjects: 30
Study 10736079 — intervention group
Group type: COMPARATOR
Intervention: Controlled mechanical ventilation (CMV) (n=16)
Number of subjects: 30
Study 8874661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 100 micrograms OD
Number of subjects: 501
Study 8874661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 micrograms OD
Number of subjects: 501
Study 8874661 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 501
Study 8874661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 1527157 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, t.i.d. for 3 weeks before surgery and added to cardioplegic solutions at 10(-6) M)
Number of subjects: 19
Study 1527157 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 19
Study 1527157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 4014786 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-metaproterenol
Number of subjects: 1450
Study 4014786 — intervention group
Group type: COMPARATOR
Intervention: Placebo-inhaler with inert ingredients
Number of subjects: 1450
Study 30902603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered implants
Number of subjects: 50
Study 30902603 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical implants
Number of subjects: 50
Study 29435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PP-SV) with inspiratory pressure of 8 cmH2O, positive end-expiratory pressure of 10 cmH2O, and fraction of inspired oxygen of 0.21
Number of subjects: 17
Study 29435810 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation at zero inspiratory pressure (ZEEP-SV)
Number of subjects: 17
Study 29435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position (RT)
Number of subjects: 17
Study 29435810 — intervention group
Group type: COMPARATOR
Intervention: Beach chair position (BC)
Number of subjects: 17
Study 29435810 — intervention group
Group type: COMPARATOR
Intervention: Supine position (S)
Number of subjects: 17
Study 27040472 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active academic lessons (22-week intervention program)
Number of subjects: 376
Study 27040472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 376
Study 25088030 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program (CBE)
Number of subjects: 19
Study 25088030 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupervised habitual physical activity)
Number of subjects: 19
Study 22536889 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 150
Study 22536889 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 150
Study 21591384 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day omega-3 polyunsaturated fatty acids for 1 month
Number of subjects: 43
Study 21591384 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day omega-3 polyunsaturated fatty acids continued for a second month
Number of subjects: 43
Study 21591384 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day omega-3 polyunsaturated fatty acids stopped after one month
Number of subjects: 43
Study 19419925 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and docetaxel (standard therapies)
Number of subjects: 0
Study 19419925 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer taxanes (in development)
Number of subjects: 0
Study 19419925 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel taxanes (single agents and in combination regimens)
Number of subjects: 0
Study 15915295 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained residents
Number of subjects: 0
Study 15915295 — intervention group
Group type: EXPERIMENTAL
Intervention: Caretakers of pediatric patients seen by intervention residents
Number of subjects: 0
Study 15915295 — intervention group
Group type: COMPARATOR
Intervention: Untrained residents
Number of subjects: 0
Study 11836041 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 95
Study 11836041 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 95
Study 11836041 — intervention group
Group type: EXPERIMENTAL
Intervention: ccHRT (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 95
Study 11836041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 9817623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + desipramine
Number of subjects: 0
Study 9817623 — intervention group
Group type: COMPARATOR
Intervention: Placebo + desipramine
Number of subjects: 0
Study 18800454 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 163
Study 18800454 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg)
Number of subjects: 163
Study 18800454 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) and Captopril (50 mg)
Number of subjects: 163
Study 2766724 — intervention group
Group type: EXPERIMENTAL
Intervention: Prentif cervical cap
Number of subjects: 0
Study 2766724 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 0
Study 651595 — intervention group
Group type: EXPERIMENTAL
Intervention: Unik
Number of subjects: 198
Study 651595 — intervention group
Group type: EXPERIMENTAL
Intervention: Unibaryt
Number of subjects: 198
Study 651595 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropaque
Number of subjects: 198
Study 651595 — intervention group
Group type: COMPARATOR
Intervention: Barex‐Coat‐S
Number of subjects: 198
Study 31780587 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) + usual care
Number of subjects: 124
Study 31780587 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124
Study 29380563 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell therapy (Stem Cells Group, n=30)
Number of subjects: 60
Study 29380563 — intervention group
Group type: COMPARATOR
Intervention: No cell therapy (Controls, n=30)
Number of subjects: 60
Study 26786756 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium oxide (Al2O3) exposure (3.8-4.0 mg/m3) for 2 hours including 30 minutes of exercise
Number of subjects: 15
Study 26786756 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium oxide (Al2O3) exposure
Number of subjects: 15
Study 26786756 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure (control)
Number of subjects: 15
Study 24214244 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning to quilt for an average of 16.51 hr a week for 3 months
Number of subjects: 0
Study 24214244 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning digital photography for an average of 16.51 hr a week for 3 months
Number of subjects: 0
Study 24214244 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in both activities (quilting and digital photography) for an average of 16.51 hr a week for 3 months
Number of subjects: 0
Study 24214244 — intervention group
Group type: COMPARATOR
Intervention: Receptive-engagement conditions (nonintellectual activities with a social group or low-demand cognitive tasks with no social contact)
Number of subjects: 0
Study 22108921 — intervention group
Group type: COMPARATOR
Intervention: Clamp (CL)
Number of subjects: 57
Study 22108921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp-free device (HS)
Number of subjects: 57
Study 20854563 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of general fatigue, physical fatigue
Number of subjects: 40
Study 20854563 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of assistive devices
Number of subjects: 40
Study 20854563 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of home help
Number of subjects: 40
Study 20854563 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of community mobility services
Number of subjects: 40
Study 20854563 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) performance
Number of subjects: 40
Study 17177576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 17177576 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to aripiprazole from maintenance therapy with another antipsychotic
Number of subjects: 0
Study 15516167 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) - wearing a plate till surgical closure of the soft palate
Number of subjects: 54
Study 15516167 — intervention group
Group type: COMPARATOR
Intervention: No intervention (IO-) - did not have a plate
Number of subjects: 54
Study 11266253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin laced collagen tampon
Number of subjects: 595
Study 11266253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gentamicin laced collagen tampon)
Number of subjects: 595
Study 9885199 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a large mirror during tasting
Number of subjects: 0
Study 9885199 — intervention group
Group type: COMPARATOR
Intervention: No mirror present during tasting
Number of subjects: 0
Study 7983603 — intervention group
Group type: EXPERIMENTAL
Intervention: 900-mg theophylline doses as three 300-mg once-a-day theophylline capsules in the morning
Number of subjects: 18
Study 7983603 — intervention group
Group type: EXPERIMENTAL
Intervention: 900-mg theophylline doses as three 300-mg once-a-day theophylline capsules in the evening
Number of subjects: 18
Study 7983603 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsules administered midway between each dose of active drug
Number of subjects: 18
Study 2660750 — intervention group
Group type: EXPERIMENTAL
Intervention: LC9018 alone
Number of subjects: 29
Study 2660750 — intervention group
Group type: EXPERIMENTAL
Intervention: LC9018 + MMC
Number of subjects: 29
Study 8218753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.d.s.; total dose 750 mg)
Number of subjects: 15
Study 8218753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8218753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 15
Study 353720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (50-225 mg daily)
Number of subjects: 0
Study 353720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 353720 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 353720 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 353720 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 0
Study 31419605 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic depression screening using the 8-item Patient Health Questionnaire (PHQ-8) and notification of primary care providers (PCPs) with invitation to participate in centralized, patient-preference, stepped depression care (Screen, Notify, and Treat)
Number of subjects: 1500
Study 31419605 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic depression screening and PCP notification only (Screen and Notify)
Number of subjects: 1500
Study 31419605 — intervention group
Group type: COMPARATOR
Intervention: Usual care (No Screen)
Number of subjects: 1500
Study 27664274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 26
Study 27664274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported risky drug use
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamines
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: History of incarceration
Number of subjects: 192
Study 27753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 192
Study 24577383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 404
Study 24577383 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature parameters
Number of subjects: 404
Study 22901554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingonberry powder with glucose (50 g)
Number of subjects: 2
Study 22901554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingonberry powder with triacylglycerols (35 g)
Number of subjects: 2
Study 22901554 — intervention group
Group type: COMPARATOR
Intervention: Control (fat-free yoghurt with glucose or triacylglycerols without lingonberry powder)
Number of subjects: 2
Study 19876045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 23
Study 19876045 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 23
Study 17877239 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice
Number of subjects: 180